Comments
Granules, a vertically integrated pharmaceutical company headquartered in Hyderabad, has announced that Granules Pharmaceuticals Inc. (GPI), its wholly owned subsidiary in Chantilly, Virginia has completed an audit by the US Food and Drug Administration (USFDA) with two minor observations.
Also read: Granules India earmarks capex of Rs 1,000 crore till FY24
This facility was inspected by the USFDA from June 21-25. The audit is a pre-approval inspection for three products filed from this facility. “We will be responding to the two observations within the stipulated time period,” said Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc.
GPI is a USFDA & DEA approved facility spread over 1,00,000 sq ft area, with established R&D & Manufacturing capabilities for low volume, oral solid dosage forms, according to a company statement.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.